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Background. The present study was designed to test the bio-
compatibility of a new vitamin E-modified multi-layer membrane
(CL-E filter), as well as its ability to protect against oxygen free
radicals during hemodialysis (HD).
Methods. We investigated, both in vitro and in vivo, the biore-
activity of the filter with respect to the blood antioxidants and its
ability to prevent lipoperoxidation. The effects on the leukocyte
respiratory burst were also studied. Cuprammonium rayon was
used as a comparison material (CL-S filter).
Results. The in vitro results demonstrated that, under controlled
conditions, CL-E is able to preserve blood antioxidants, and
particularly vitamin E, from the spontaneous consumption ob-
served in the incubation with CL-S filters and in control incuba-
tions. In accordance with this observation, the rate of the oxidative
demolition of lipids either in plasma and red blood cells (RBC) or
from rat brain homogenate decreased after the exposure to CL-E
filters in comparison with the CL-S filter. Moreover, in the
absence of any significant cytotoxic effects due to both the types of
material studied, the production of oxygen free radicals and nitric
oxide (NO) by leukocytes was higher after their in vitro exposure
to CL-S, but was quite similar to that of the control leukocytes
after exposure to CL-E. In vivo, a one-month treatment with the
CL-E filter increased plasma vitamin E by 84.3% with respect to
treatment with CL-S; this gain slightly decreased to 68.9% when
CL-E treatment was prolonged to three months. In the RBC,
vitamin E was found to have increased by 76.7% and 113.4% at
one and three months, respectively. Plasma glutathione (GSH)
levels determined at three months were significantly increased
from 0.10 6 0.02 to 0.33 6 0.12 mmol/ml, while the erythrocyte
GSH was only slightly increased. The leukocyte function esti-
mated as responsiveness to soluble chemical stimuli in CL-S-
treated patients was significantly improved both qualitatively and
qantitatively after CL-E treatment. The presence of an increased
number of mononuclear cells undergoing programmed cell death
(apoptosis) in CL-S-treated patients (18.8 6 1.7% vs. a control
value of 6.5 6 2.3%) as well as the apoptogenic effect of their
plasma in vitro on U937 cells was significantly corrected after
CL-E treatment (mean decrease in apoptotic mononuclear cells at
24 hours of culture, 25.5% and 27.1% at 1 and 3 months,
respectively). The anti-apoptogenic effect of CL-E treatment
showed a close dependence on the increase in vitamin E in the
blood cell compartment.
Conclusions. This study suggests that this vitamin E-modified
membrane can be considered a highly biocompatible material, the
antioxidant properties of which can exert a site-specific and timely
scavenging function against oxygen free radicals in synergy with a
hypostimulatory action on the PMN respiratory burst.
As a consequence of their low biocompatibility, hemodi-
alysis (HD) membrane materials have been demonstrated
to activate the oxidative metabolism of polymorphonuclear
(PMN) cells and monocytes/macrophages [1–3]. These
activated leukocytes generate oxygen free radicals (OFR)
that react strongly against a wide spectrum of biomolecules
[4, 5], resulting in a series of cytotoxic effects commonly
described as “oxidative stress.” This condition has been
demonstrated to contribute to the pathogenesis of some
complications such as cataract, b2-microglobulin amyloid
arthropathy and atherosclerosis [3, 6], commonly associ-
ated with HD and thus many efforts have been made to
combat it, including those aimed at improving the biocom-
patibility of the materials used [7, 8].
Among the materials used for HD, regenerated cellulose
has long been employed thanks to its excellent dialysis
performance and stability. Nevertheless, this material has
been observed to have a low biocompatibility and to acutely
stimulate oxidative metabolism in leukocytes [2, 9–12].
While synthetic membranes have significantly improved
biocompatibility, the problem of OFR production during
HD remains largely unresolved [13], probably due to the
insufficient level of biocompatibility achieved and the mul-
tiple effects of the mechanisms involved in OFR produc-
tion [3].
In an attempt to increase the quality of HD filters, an
innovative material was recently proposed with the dual
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goals of obtaining an improvement in biocompatibility and
a specific protection against OFR. This biomaterial consists
of a multi-layer membrane modified on the blood surface
to support a coating of the liposoluble physiological anti-
oxidant vitamin E. In previous studies [14–16], we and
other authors reported that vitamin E-modified filters can
be effective in protecting HD patients against OFR damage
by decreasing PMN activation and providing a better
control of the blood lipoperoxidation and antioxidant sta-
tus. However, this evidence had not been supported by
studies that specifically characterized the OFR-scavenging
function of vitamin E when bound to the dialysis membrane
surface. With this in mind, we investigated in vitro the redox
cycling properties of this molecule with respect to the
antioxidants constitutively present in the plasma and red
blood cells (RBC), simultaneously evaluating the ability of
the vitamin E-modified membrane to protect against li-
poperoxidation. The leukocyte oxidative burst resulting
from the in vitro exposure to the standard material cupram-
monium rayon and to the vitamin E-modified membrane
was also studied. In addition, we evaluated in vivo the
effects of treatment with the vitamin E-modified filter,
determining blood vitamin E levels and the deree of lipid
unsaturation, as well as PTH function and apoptosis in
mononuclear leukocytes, in a group of chronic HD pa-
tients.
METHODS
Materials
Heparinized blood samples from healthy human donors
used in the in vitro studies were generously provided by Dr.
Picardi of the Blood Bank of the Urbino Hospital. Blood
samples were maintained at 4°C until use (within two days)
or immediately processed as described below before load-
ing into the dialysis filters and for the laboratory determi-
nations.
All the materials used both in the in vitro and in the in
vivo protocols, including dialysis filters, blood lines and
connections were from Terumo (Terumo Corporation,
Japan). Two kinds of filter membranes with an equivalent
dialysis performance were tested: a series consisting of a
cuprammonium rayon membrane, Clirans® S15 (CL-S) and
a series consisting of a multi-layer vitamin E-coated mem-
brane, Excebrane®, Clirans® E15 (CL-E). Figure 1 shows
the structure of the modification with vitamin E of the
Excebrane® membrane. A block polymer composed of a
hydrophilic polymer and a fluorocarbon resin was chemi-
cally fixed to the hydroxyl groups on the cellulose surface.
The fluorocarbon resin constitutes a hydrophobic support
for the binding of the long-chain unsaturated aliphatic
alcohols (oleic alcohols), which, besides exerting an inhib-
itory function on platelet activation, hydrofobically bind
vitamin E. The amount of vitamin E bound to the blood
surface of the filter as d-a-tocopherol was 140 mg/m2
surface.
In vitro study
Hemodialysis filters, on which dialysate outlet and inlet
connections had been closed to avoid the efflux of filtrate
and solutes from the blood through the membrane, were
filled with washing solutions (NaCl 0.9% or PBS), whole
blood or plasma using a peristaltic pump. After a priming
procedure, the filters were filled with blood or other
solutions as below and, together with corresponding ali-
quots maintained in glass vials (control), were incubated at
room temperature. After a set of preliminary tests, exclud-
ing the presence of a significant amount of hemolysis even
after a long time of exposure (4 hr), the following experi-
mental times were chosen to characterize the effects of the
membrane on blood or other solutions: (a) 15 minutes
(short-time exposure) and (b) 60 minutes (long-time expo-
sure). At these times, 10 ml of blood were collected and
treated for the separation of plasma and RBC samples, as
previously described [17].
In some experiments lipoperoxides (LOOH), partially
purified from a rat brain homogenate by extraction in
ethanol/hexane (2/5, vol/vol) followed by evaporation and
reconstitution in PBS, were exposed as above to the HD
filters in the presence or absence of 100 mM vitamin C and
500 mM GSH. The lipoperoxide suspension in the absence
of antioxidants produced a nearly linear rate of MDA
formation within 20 minutes after its reconstitution in PBS
at 20°C.
Fig. 1. Schematic structure of the surface
modification in the CL-E filters.
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In vivo study
A group of 15 uremic patients (7 male and 8 female) with
a mean age of 68.4 6 5.8 years who were undergoing
chronic HD (dialytic age of 35.1 6 28.6 monhs) and a group
of 10 sex- and age-matched healthy controls were selected.
In the patients, the primary renal diseases were: glomeru-
lonephritis (N 5 5), nephroangiosclerosis (N 5 4), chronic
interstitial nephritis (N 5 2), polycystic kidney disease (N 5
1) and unknown (N 5 3). After a sufficient period of
treatment with the CL-S filter (3 or more months) patients
underwent HD using the CL-E filter. Thus, laboratory
determinations were carried out before and after one and
three months of treatment with the CL-E membrane.
Venous blood samples were drawn in heparinized tubes
and processed within five hours from the drawing.
Assay procedures for the antioxidants
Vitamin E was measured with the method described by
Miki et al [18]. Ascorbic acid (AA) and its oxidized form
dehydroascorbic acid (DHA) were measured according to
the method of Moeslinger et al [19]. Reduced glutathione
(GSH) and related enzyme activities (glutathione reduc-
tase, selenium-dependent glutathione peroxidase and glu-
tathione S-transferase) were determined as previously de-
scribed [17, 20].
Assay of lipid composition and lipoperoxidation
The fatty acid composition in the plasma lipids and RBC
membranes was determined by gas chromatography after
isopropylic esterification [21]. The formation of malondial-
dehyde (MDA), one of the main aldehydic coumpounds
recognized after peroxidative demolition of the lipids, was
measured by a thiobarbituric acid test and direct HPLC
analysis, as previously described [20].
Determinations on leukocytes
In some experiments leukocytes were separated from
fresh blood, and contaminating RBC were subjected to
hypotonic lysis as described by Markert and Wauters [22].
The leukocyte-rich suspension obtained after dilution in
PBS enriched with glucose and albumin [23] was used for
the incubations in the filters.
In the in vivo experiments, the susceptibility of the
leukocyte to exogenous stimuli was evaluated as an index of
their function by measuring the luminol-dependent chemi-
luminescence (LDC) on whole blood produced in vitro as
below for the respiratory burst assay.
Leukocyte number and subpopulation composition (lym-
phocytes, PMN and monocytes) were evaluated both by
hemocytometry and cytofluorimetry; viability was tested
using propidium iodide inclusion.
Cell death studies
Apoptosis and necrosis were evaluated both immediately
before the exposure to the HD filters and after cell culture
for 24 hours (see below) either by direct morphological
observation of the cells or alternatively by cytofluorimetry
using the viability test described above and the TUNEL
method (Boehringer Mannheim). In the in vivo study the
mononuclear leukocytes were separated by density gradient
[23], and then after washing in 0.9% NaCl were resus-
pended in RPMI 1640 medium supplemented with 10%
FCS and antibiotics, and then maintained in culture in a
humidified atmosphere of 5% CO2/95% air at 37°C for four
hours. The apoptogenic properties of uremic plasma, were
tested on the U937 monocyte-macrophage cell line using
the same culture conditions as above for mononuclear cells.
Nuclear morphology was assayed to evaluate apoptotic cell
number. The cells were stained with Hoechst 33342 and
analyzed by fluorescence microscopy; the apoptotic mor-
phology was quantified calculating the percent fraction of
cells with a fragmented nucleus among the total cell
population. At least 300 cells in five or more randomly
selected fields were scored in each slide.
Respiratory burst assay
Luminol-dependent chemiluminescence (LDC) was de-
termined on the leukocyte suspension or whole blood as
described by Allen [23], with the exception that in the in
vitro study the stimulation of the leukocyte oxidative me-
tabolism was induced by 15 nM phorbol 12-myristate 13-
acetate (PMA), which corresponds to a subliminal stimu-
latory concentration of this mitogen causing specific
degranulation and activation of redox metabolism in PMN.
This expedient was adopted to obtain a leukocyte popula-
tion susceptible to activation and LDC values sufficient for
the measurement. In the in vivo study the concentration of
PMA was 150 nM. A model 1500 Tri-Carb® liquid scintil-
lation analyzer from Packard (Zurich, Switzerland), set in
the out-of-coincidence mode, was used to determine pho-
ton emission (KeV range, 0 to 6.5).
Nitric oxide (NO) production was determined using the
Griess reagent [24] on the cell suspension supernatant over
a three-hour period of exposure of the leukocytes to the
filters, in the presence or absence of PMA as above.
RESULTS
Table 1 shows the levels of the antioxidants constitutively
present in the plasma and RBC after a short-time exposure
(15 min) to the vitamin E-modified membrane and to the
cuprammonium rayon membrane. In the plasma, vitamin E
was highly recovered after the exposure to CL-E filters,
whereas the recovery was drastically lower after the expo-
sure to CL-S filters. In a similar way, CL-E largely pre-
served the levels of vitamin C from the spontaneous
oxidation to DHA, whereas CL-S filters induced a level of
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oxidation for vitamin C twice that observed using CL-E
filters. Reduced glutathione levels showed a different trend
than vitamin E and C, decreasing after the exposure to
CL-E with respect to the CL-S filters. Further investigation
of this result confirmed a specific requirement for GSH in
the in vitro bioreactivity of the vitamin E bound to the CL-E
filters in the presence of lipid peroxidation (Fig. 2). In the
RBC, in the presence of a low recovery of vitamin E, a
better antioxidant status with a higher cytosolic GSH was
found in CL-E-exposed samples with respect to those
exposed to CL-S. Long-time incubation (from 60 min to
120 min) with the two types of filter caused a massive
time-dependent consumption of vitamin E, vitamin C and
GSH in the plasma (.75% in all cases after 120 min of
exposure). In the RBC, an exposure to the CL-S filter for a
time longer than 60 minutes decreased vitamin E levels by
26% while in CL-E-exposed samples the vitamin E content
was unchanged.
Glutathione-related enzymes were not influenced by the
exposure to the two types of membrane (Table 1).
Erythrocyte and plasma lipid compositions are shown in
Table 2. Plasma and RBCs exposed for a short time to
CL-E showed levels of polyunsaturated fatty acids (PUFA)
higher than those observed in the samples exposed to CL-S
filters. A detailed evaluation of the plasma fatty acid
composition revealed that linoleic acid (18:2), arachidonic
acids (20:4) and eicosapentaenoic acid (20:5) were signifi-
cantly preserved during the exposure to the CL-E versus
the CL-S filter. The preservation of the RBC fatty acid
unsaturation was mainly related to the docosahexaenoic
acid (22:6) levels and only to a small degree to linoleic acid
(18:2), while other unsaturated species were rapidly lost. A
longer time of exposure (60 min) affected plasma lipid
composition by decreasing PUFA levels and consequently
increasing the levels of monounsaturated fatty acids
(MUFA) and saturated fatty acids (SFA); this effect was
greater in the samples treated with CL-E filters. The assay
of MDA confirmed these results (not shown).
The antioxidant function of the vitamin E bound to the
modified membrane was also characterized with respect to
its ability to utilize AA and GSH in preventing MDA
formation during the spontaneous decomposition of
LOOH purified from rat brain homogenate and thus in the
presence of a high flux of free radicals produced by LOOH
decomposition (Fig. 2). Incubation with the CL-E mem-
brane induced a pronounced lag phase in the MDA forma-
tion curve that was related to a consumption of the
antioxidants (AA and GSH) added to the incubation
mixture measured as production of their oxidative subprod-
ucts DHA and GSSG. These effects were not observed in
the presence of the CL-S filter.
Table 3 shows the in vivo effect on blood vitamin E levels
of a group of chronic HD patients stabilized with the CL-S
filter who were shifted to treatment with the CL-E filter.
The one-month treatment with the CL-E filter increased
the vitamin E levels both in plasma and in the RBC by
84.3% and 76.7%, respectively. However, the vitamin E
levels in the patients treated with the CL-S filter were not
significantly lower than in the controls. After three months
of treatment, the plasma vitamin E levels either had not
increased further or had slightly decreased (68.9% of the
value in CL-S), while RBC vitamin E increased by a further
36.7%, for a total gain of 113.4%. The levels of the PUFA
arachidonic acid (20:4), which was chosen as an index to
evaluate lipoperoxidation in plasma, were lower in the
patients in HD with the CL-S filters (0.3 6 0.2 of the total
lipids) with respect to controls (2.0 6 0.9%), but had
increased to 2.9 6 1.6% after one month of treatment with
the CL-E filter (P , 0.001 vs. CL-S). Plasma GSH levels
determined at three months of treatment with the CL-E
filter were increased from 0.10 6 0.02 to 0.33 6 0.12
mmol/ml, while the erythrocyte GSH was only slightly
increased (not shown).
The analysis of the respiratory burst induced in vitro
following the incubation of a leukocytes suspension with
the two types of filters in the presence of a subliminal
stimulation by PMA showed LDC levels six and three times
higher at 15 minutes and 30 minutes of incubation, respec-
tively, with the CL-S filter compared to the CL-E filter (Fig.
3). The latter type of membrane induced a LDC emission
similar to that of the control leukocytes (without exposure
to any material) after the subliminal stimulation. In a
similar way, NO production was significantly lower in the
supernatant recovered from the leukocyte suspension ex-
posed to CL-E after subliminal activation with PMA,
whereas CL-S induced a significant release of NO. Total
leukocyte population viability was not statistically different
in the samples after exposure to the two types of mem-
branes in vitro ($87%, after 60 min of exposure). Similarly,
the viability and composition of the leukocyte subpopula-
tions were not affected by the exposure to both the filter
types. Under these conditions, only aspecific necrotic pro-
cesses were observed, and morphological studies and
Table 1. Plasma and erythrocyte antioxidants after in vitro exposure to
CL-S and CL-E filters
Filter type
Sample
CL-S CL-E
Plasma RBC Plasma RBC
Vitamin E 28.6 6 7.7 20.9 6 10.7 76.5 6 8.1a 46.5 6 3.6b
Vitamin C 22 6 5 ND 46 6 5b ND
GSH 41 6 4 72 6 12 18 6 9b 99 6 15b
GPx 79.3 6 9.9 95.6 6 12.8 96.1 6 13.3 88.7 6 9.5
GST ND 90.1 6 14.8 ND 81.6 6 12.4
Abbreviations are: CL-S, caprammonium rayon; CL-E, vitamin E-mod-
ified multi-layer membrane; GSH, glutathione; GPx, glutathione peroxi-
dase; GST, glutathione-S-transferase; RBC, red blood cells.
Data are expressed as percent of a mean control value calculated from
four experiments using the same blood samples exposed (time 5 15 min)
to the filters and maintained at room temperature. ND is not determined.
Statistical analysis is by Student’s t-test.
a P , 0.05 and b P , 0.01, CL-E vs. CL-S filters.
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TUNEL determination revealed the absence of a different
susceptibility to apoptotic processes when the cells were
cultured for 24 hours after exposure to CL-S and CL-E
filters for 120 minutes (data not shown).
Stimulated LDC in the whole blood of CL-S treated
patients, measured before HD, was quantitatively compa-
rable (peak height) but delayed (peak time) in comparison
with controls (data not shown). After one month of treat-
ment with the CL-E filter, the response to PMA stimulation
was strongly higher (peak height increased by more than 5
times) and, to a lesser extent, earlier (peak time decreased
by 30%) with respect to starting values. Apoptotic cell
death in circulating mononuclear cells was observed to be
significantly augmentd in CL-S treatment (18.8 6 1.7%)
Fig. 2. Effect of CL-S (dashed line) and CL-E
(solid line) filters on lipoperoxidation and
antioxidant consumption in a buffered
suspension of lipoperoxides (LOOH) purified
from rat brain homogenate. (A) In these
experiments, malondialdehyde (MDA)
formation was determined by thiobarbituric
acid test. The LOOH suspension was incubated
in the filters as described in the Methods
section with (f, F) or without (M, E) 500 mM
of reduced glutathione (GSH) and 100 mM
ascorbic acid (AA). (B) In the case of the
presence of these antioxidants their oxidation
subproducts, namely oxidized glutathione
(GSSG; f, F) and dehydroascorbic acid (DHA;
M, E), were measured. Data are the mean 6
SD of five experiments performed in duplicate.
Table 2. Erythrocyte and plasma lipid composition after exposure in
vitro to CL-S and CL-E filter membranes
Lipid components PUFA MUFA SFA
Erythrocyte
Control 28.2 6 2.4 30.2 6 3.8 41.5 6 4.4
CL-S 29.3 6 2.7 28.6 6 2.9 37.9 6 3.0
CL-E 35.7 6 4.3a 25.5 6 5.0 38.5 6 8.1
Plasma
Control 17.9 6 2.9 28.0 6 2.5 53.8 6 4.8
CL-S 16.2 6 3.5 29.8 6 4.9 52.7 6 9.8
CL-E 20.5 6 4.7a 30.3 6 8.0 49.2 6 6.5
Abbreviations are: PUFA, polyunsaturated fatty acids; MUFA, mono-
unsaturated fatty acids; SFA, saturated fatty acids.
Data are expressed as percent of a control value as described in Table
1. Incubation conditions are those described in the methods section.
Statistical analysis (Student’s t-test.): a P , 0.05, CL-E vs. CL-S and
b P , 0.05, incubation time 5 min vs 60 min.
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versus CL-E treatment (14.0 6 3.5% and 13.7 6 5.7%,
respectively at 1 and 3 months) and controls (6.5 6 2.3%;
Fig. 4). Uremic plasma in CL-S also showed an apoptogenic
effect on U937 in culture that was decreased in CL-E and
absent in control plasma (not shown). Vitamin E content in
RBC membranes and levels of apoptosis in the mononu-
clear cells were inversely correlated (r 5 20.960).
DISCUSSION
A growing body of evidence points to a defective antiox-
idant/prooxidant balance as a pathogenic factor in some
common HD-related side effects such as: anemization,
defective immunological and coagulative functions, accel-
erated atherosclerosis and aging, b2-microglobulin amyloid
arthropathy and cancer onset [3, 6, 17, 25, and the refer-
ences therein]. In this context, the lack of antioxidant
protection, and in particular a deficit of vitamin E, has long
been a subject of investigation [26–28]. At the same time,
an increased prooxidant stimulus from PMN activated by
the bioincompatibility of HD materials has been suggested
[1–3], but is not yet completely understood.
In this study we evaluated, both in vitro and in vivo, the
antioxidant properties of a vitamin E-modified multi-layer
membrane, which for the first time in HD practice intro-
duces the concept of a membrane bearing a dual function
of filtration and the properties of a highly biocompatible
bioreactor.
The vitamin E bound to the filter interacts in vitro with
the plasma antioxidants, preventing in part the peroxida-
tion of the plasma and cell membrane lipids as assayed by
lipid composition and MDA formation. This effect is
related with a net consumption of GSH that is converted to
the corresponding oxidized form (GSSG). Under the ex-
perimental conditions used herein, GSSG cannot be recon-
verted to GSH due to the absence of the metabolic support
of the hepatic hexose monophosphate shunt. This pathway
utilizes glucose to produce reducing equivalents that are
transferred to the coenzyme nicotinamide adenine dinucle-
otide phosphate (NADP1), thus forming its corresponding
reduced form (NADPH) [17]. The limitation of this in vitro
model is absent under physiological conditions following
the classical reaction scheme, shown in Figure 5. In fact,
GSH and AA support the electron transfer chain restora-
tion of vitamin E from its corresponding tocopheryl and
tocopheroxyl radicals formed in the scavenging reaction of
the lipoperoxyl radicals (LOOz) generated in the plasma
and cell membrane by the OFR attack on the polyunsatu-
rated lipids [6].
Under the conditions observed in the long-time exposure
experiments, the massive consumption of the antioxidants
physiologically present in the blood made the conversion of
the vitamin E bound to the CL-E filters from the tocoph-
eryl(oxyl) radical form to the tocopherol form poorly
Fig. 3. Luminol-dependent chemiluminescence (LDC) production over
time after in vitro phorbol 12-myristate 13-acetate (PMA) stimulation of
leukocytes exposed for 15 and 30 minutes to CL-S (s) and CL-E (o)
filters. One 3 104 leukocytes/ml were suspended in PBS plus glucose and
albumin (both at a final concentration of 0.1% wt/vol) at a final volume of
2 ml in the presence of 10 mM luminol and 15 nM PMA. Viability at 15
minutes and at 30 minutes was 89% and 91%, respectively. The data are
expressed as mean 6 SD of five measurements, and represent the
integration area of the photon emission curves recorded as described in
the Methods section. *P , 0.001 CL-S vs. CL-E.
Table 3. Blood vitamin E levels in chronic HD patients treated with CL-S and CL-E filters
Plasma mg/liter Erythrocyte mg/liter cells
Pre-HD Post-HD Pre-HD Post-HD
CL-S 14.50 6 4.64b 16.44 6 4.77b 0.30 6 0.11b 0.49 6 0.15c
CL-E (1 month) 26.73 6 9.00 (84.3%) ND 0.53 6 0.21 (76.7%) ND
CL-E (3 months) 24.49 6 6.41 (68.9%) 26.35 6 8.66 (62.4%) 0.64 6 0.31 (113.4%) 0.80 6 0.19 (61.2%)
A longitudinal study was carried out over a six-month period of time. Fifteen end-stage renal disease subjects were stabilized in HD with CL-S filters
and thus shifted to CL-E filter. Five healthy controls were also studied.a The vitamin E levels were determined at each step as described in the Methods
section.
a Vitamin E levels in the control plasma (mg/liter) and RBC (mg/liter) were respectively 16.18 6 7.37 and 0.41 6 0.12. Data in parentheses indicate
the percent increase in comparing CL-E vs. CL-S mean values.
ANOVA test for repeated measures: b P , 0.001 vs. CL-E 1 month, CL-E 3 months and CL-S 3 months; c P , 0.001 vs. CL-E 3 months and CL-S
3 months; ND is not determined.
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probable or even impossible. Thus, the exhaustive con-
sumption of the antioxidants in vitro can be a critical event
that may justify a prooxidant activity of vitamin E, which
depends on the flux of the radical species formed in the
medium [29]. Keeping this in mind, we observed that in the
presence of a high OFR flux, generated by LOOH purified
from rat brain homogenate, only CL-E and not CL-S filters
are able to interact with the auxiliary antioxidants added to
the incubation medium, namely GSH and AA. These data
definitively confirm the redox cycling properties of the
vitamin E bound to the filter membrane. At the same time,
it is likely that in the plasma, in the presence of a more
complex antioxidant system [30–33] that controls the con-
centration of LOOH and thus the OFR flux, the redox
cycling properties of the CL-E membrane suppress lipoper-
oxidation. Under the same conditions CL-S was observed
to induce a slight prooxidant effect correlated with a
proactivating effect on the leukocyte oxidative metabolism
that was absent in CL-E.
To definitively characterize the CL-E membrane prop-
erties and their clinical relevance, in this study we first
evaluated the in vivo effect of the CL-E membrane on
blood antioxidant defenses. In this study the 1-month
treatment with the CL-E filter was sufficient to increase the
plasma vitamin E levels in pre-HD by 45.7%, and no
further increases were observed at three months of treat-
ment. In the RBC increases of 43.4% and 53.1% were
observed after one and three months of treatment with the
CL-E membrane, respectively. The potentiation of the
vitamin E levels, in agreement with the previous observa-
tion of Costagliola and Menzione [34], corresponded to an
increased GSH-dependent protection in both plasma and
RBC. At the same time the levels of arachidonic acid in
plasma were found to be ten times higher. The levels of
arachidonic acid, one of the most abundant polyunsatu-
rated lipids in plasma, were chosen as the index to measure
lipoperoxidation because of their greater reliability than
other parameters, such as MDA determined with the
thiobarbituric acid test. In fact, this latter assay is known to
be a less specific and indirect method for studying lipoper-
oxidation, which, although useful for its versatility in in vitro
studies, is not recommended for application in clinical
evaluations [35]. The possibility of increasing the antioxi-
dant defenses by the administration of one or more mole-
cules such as a-tocopherol and GSH has long been inves-
tigated in HD patients [31–33] given their increased of
oxidative stress [17, 28]. However, all the previous thera-
peutical approaches have been based on oral or parenteral
administrations of antioxidants, which, unlike treatment
with the CL-E filter, cannot offer a specific and timely
protection against OFR at the site of their generation by
activated PMN.
Regarding the biocompatibility of the CL-E membrane,
it induced a lower in vitro activation of the leukocyte
oxidative burst, measured as LDC emission and NO pro-
duction, in comparison with the CL-S membrane, a result
observed in the absence of any significant cytotoxic effect
following the exposure to either of the membrane types.
The detailed mechanism by which the vitamin E-modified
membrane can decrease leukocyte activation is still largely
unclear. However, the low responsiveness to subliminal
levels of PMA observed after the exposure to this material
Fig. 4. Effect of treatment with CL-E and CL-S
on apoptosis of mononuclear leukocytes and its
correlation with the plasma and red blood cell
(RBC) vitamin E levels. Apoptosis was
determined by fluorescence microscopy of
nuclear morphology and expressed as the
percentage of cells bearing fragmented nuclei
among the total cell population, counting at
least 300 cells in at least 5 randomly selected
fields. The determinations were carried out
after 24 hours of colture as described in the
Methods section. The mean value of apoptotic
cells in the controls was 6.5 6 2.3%. Data
represent the mean 6 SD calculated from two
cell specimens per subject counted twice by two
different operators. Symbols are: () RBC
vitamin E; (F) plasma vitamin E; (f) apoptotic
cells. *P , 0.05 and #P , 0.01. time 0 versus 1
and 3 months.
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versus the cuprammonium rayon may be ascribed either to
a specific effect of vitamin E or to the effect of other
membrane-surface modifiers, such as oleic alcohol resi-
dues, on both the cell membrane lipid composition and
antioxidants. This aspect, which is under investigation,
could explain the role of CL-E in preventing platelet
activation during HD [15], one of the potential applications
for this filter. Other effects related to an increased biocom-
patibility of the CL-E membrane were described and
concern a decreased complement activation and LDL
oxidation [14, 15].
The role of vitamin E as a lipophilic antioxidant has been
widely investigated in the context of cell protection against
oxidative stress, a condition that can influence some cell
functions, including the receptor function and related
signal transduction pathways [36]. For instance, both
monocyte and platelet functions are critically influenced by
membrane lipid composition and oxidative stress [15, 37,
38], and one of the most important consequences of
vitamin E supplementation in these cells, together with
plasma lipoproteins oxidative susceptibility, could regard
the control of the risk of atherosclerosis in HD [6, 38].
Another aspect concerning blood cell function and bio-
compatibility in HD is the presence of an increased number
of apoptotic mononuclear cells (lymphocytes and mono-
cytes) in chronic HD patients. This phenomenon is still
poorly understood, but may have a profound impact on the
immune function of HD patients [39, 40]. In the present
study, the subjects treated with the CL-S filters showed an
increased number of mononuclear cells with apoptotic
features with respect to the CL-E treated patients. How-
ever, on the basis of the observation of Heidenreich et al
[39] that high-flux polysulphone does not induce a different
extent of apoptosis in monocytes with respect to the less
biocompatible material cuprophan, and given the results
observed herein, it seems probable that the correction of
Fig. 5. Interaction between hydrophilic antioxidants and vitamin E in the scavenging of lipoperoxides in the cell membrane and plasma lipids.
Abbreviations are: L, polyunsaturated fatty acid; Vit. E (z), tocopherol and tocopheryl radicals; Vit. C (z), ascorbic acid and dehydroascorbic radical; GSH
and GSSG, reduced and oxidized glutathione; NADP1 and NADPH, nicotinamide adenine dinucleotide phosphate, oxidized and reduced forms;
HMPS, hexose monophosphate shunt. (1) Hexose monophosphate shunt activity (glucose-dependent); (2) glutathione reductase activity; (3) glutathione
peroxidase activity.
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apoptosis by CL-E treatment depends on the modifications
to the blood antioxidants, and particularly on cellular
vitamin E, rather than on a higher biocompatibility. Oxi-
dative stress is one of the pathophysiological stimuli trig-
gering or accompanying apoptosis in several human cell
lines, and antioxidants can play a role in regulating it
[41–43]. Thus, a protective effect against apoptosis in the
mononuclear cells of HD patients is likely to occur follow-
ing the increase of the cellular vitamin E obtained by CL-E
treatment. Other mechanisms able to explain the decrease
in apoptosis following vitamin E supplementation are un-
der investigation and may be related to the role of this
molecule in the control of leukocyte activation and the
release of cytokines (such as TNFa or IL-1b), which are
both responsible for the induction of apoptosis [40], and
more generally with all the factors able to interfere with
transcription and the cell cycle [44].
Another defect found in chronic HD patients is a de-
creased responsiveness of leukocytes to soluble and partic-
ulate stimuli [45]. Phorbol esters, which cause a specific
degranulation and activation of redox metabolism in PMN,
can be used to study this phenomenon as one of the most
reliable indices of a defective leukocyte function in vivo
[23]. In the HD patients an intrinsic defect due to the
uremic condition and/or a chronic exposure to bioincom-
patible materials can be responsible for this impairment in
the leukocytes. Our findings demonstrate that the treat-
ment with the CL-E filter improves, both quantitatively and
qualitatively, the responsiveness to the mitogen PMA mea-
sured as whole blood LDC emission. This effect of CL-E
treatment on leukocyte function appears to be associated
with the inhibition of mononuclear cell apoptosis. Thus, it
may represent an important and specific solution to the
increased susceptibility to infections in HD patients.
In conclusion, this study demonstrates that the CL-E
membrane can specifically interact both in vitro and in vivo
with the dynamic concentration/distribution equilibrium of
the endogenous antioxidants in the blood, and with vitamin
E in particular, by supplementing these defenses and
protecting against lipoperoxidation. In addition, in vitro
experiments indicate that CL-E can exert a site-specific and
timely scavenging function against OFR, in synergy with a
hypostimulatory action on the PMN respiratory burst. Low
platelet activation [15], together with the antiapoptogenic
function on mononuclear leukocytes and the restoration of
phagocyte function herein described in vivo, are other
clinically relevant effects of this vitamin E-modified mem-
brane.
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APPENDIX
Abbreviations used in this article are: AA, ascorbic acid; CL-E, vitamin
E-modified multi-layer membrane; CL-S, cuprammonium rayon mem-
brane; DHA, dehydroascorbic acid; GSH, glutathione; GSSG, oxidized
form of GSH; HD, hemodialysis; LDC, luminol-dependent chemilumines-
cence; LOOz, lipoperoxyl radicals; LOOH, lipoperoxides; MDA, malon-
dialdehyde; MUFA, monounsaturated fatty acids; NADP, nicotinamide
adenine dinucleotide phosphate; NO, nitric oxide; OFR, oxygen free
radical; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonu-
clear; PUFA, polyunsaturated fatty acids; RBC, red blood cell; SFA,
saturated fatty acids.
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